[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse EGR2

Summary
SymbolEGR2
Nameearly growth response 2
Aliases Krox-20 homolog, Drosophila; KROX20; early growth response 2 (Krox-20 homolog, Drosophila); AT591; CMT1D; KR ......
Chromosomal Location10q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus.
Domain PF11928 Domain of unknown function (DUF3446)
Function

Sequence-specific DNA-binding transcription factor. Binds to two specific DNA sites located in the promoter region of HOXA4. ; FUNCTION: E3 SUMO-protein ligase helping SUMO1 conjugation to its coregulators NAB1 and NAB2, whose sumoylation down-regulates EGR2 own transcriptional activity.

> Gene Ontology
 
Biological Process GO:0001503 ossification
GO:0003002 regionalization
GO:0006611 protein export from nucleus
GO:0006913 nucleocytoplasmic transport
GO:0007272 ensheathment of neurons
GO:0007389 pattern specification process
GO:0007409 axonogenesis
GO:0007411 axon guidance
GO:0007422 peripheral nervous system development
GO:0007517 muscle organ development
GO:0007519 skeletal muscle tissue development
GO:0007611 learning or memory
GO:0007622 rhythmic behavior
GO:0008045 motor neuron axon guidance
GO:0008366 axon ensheathment
GO:0010001 glial cell differentiation
GO:0014037 Schwann cell differentiation
GO:0014706 striated muscle tissue development
GO:0016925 protein sumoylation
GO:0018205 peptidyl-lysine modification
GO:0021545 cranial nerve development
GO:0021546 rhombomere development
GO:0021561 facial nerve development
GO:0021569 rhombomere 3 development
GO:0021571 rhombomere 5 development
GO:0021593 rhombomere morphogenesis
GO:0021594 rhombomere formation
GO:0021602 cranial nerve morphogenesis
GO:0021604 cranial nerve structural organization
GO:0021610 facial nerve morphogenesis
GO:0021612 facial nerve structural organization
GO:0021658 rhombomere 3 morphogenesis
GO:0021660 rhombomere 3 formation
GO:0021664 rhombomere 5 morphogenesis
GO:0021666 rhombomere 5 formation
GO:0021675 nerve development
GO:0021783 preganglionic parasympathetic fiber development
GO:0030278 regulation of ossification
GO:0030902 hindbrain development
GO:0032868 response to insulin
GO:0035282 segmentation
GO:0035283 central nervous system segmentation
GO:0035284 brain segmentation
GO:0035914 skeletal muscle cell differentiation
GO:0042063 gliogenesis
GO:0042552 myelination
GO:0043434 response to peptide hormone
GO:0044708 single-organism behavior
GO:0045444 fat cell differentiation
GO:0048167 regulation of synaptic plasticity
GO:0048168 regulation of neuronal synaptic plasticity
GO:0048483 autonomic nervous system development
GO:0048486 parasympathetic nervous system development
GO:0048511 rhythmic process
GO:0048532 anatomical structure arrangement
GO:0048667 cell morphogenesis involved in neuron differentiation
GO:0050804 modulation of synaptic transmission
GO:0050890 cognition
GO:0051168 nuclear export
GO:0051169 nuclear transport
GO:0060537 muscle tissue development
GO:0060538 skeletal muscle organ development
GO:0061564 axon development
GO:0097485 neuron projection guidance
GO:1901652 response to peptide
Molecular Function GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding
GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0000987 core promoter proximal region sequence-specific DNA binding
GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001085 RNA polymerase II transcription factor binding
GO:0001102 RNA polymerase II activating transcription factor binding
GO:0001159 core promoter proximal region DNA binding
GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding
GO:0003682 chromatin binding
GO:0008134 transcription factor binding
GO:0016874 ligase activity
GO:0031625 ubiquitin protein ligase binding
GO:0033613 activating transcription factor binding
GO:0044389 ubiquitin-like protein ligase binding
GO:0071837 HMG box domain binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-5619507: Activation of HOX genes during differentiation
R-HSA-5617472: Activation of anterior HOX genes in hindbrain development during early embryogenesis
R-HSA-1266738: Developmental Biology
R-HSA-381340: Transcriptional regulation of white adipocyte differentiation
Summary
SymbolEGR2
Nameearly growth response 2
Aliases Krox-20 homolog, Drosophila; KROX20; early growth response 2 (Krox-20 homolog, Drosophila); AT591; CMT1D; KR ......
Chromosomal Location10q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between EGR2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolEGR2
Nameearly growth response 2
Aliases Krox-20 homolog, Drosophila; KROX20; early growth response 2 (Krox-20 homolog, Drosophila); AT591; CMT1D; KR ......
Chromosomal Location10q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of EGR2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen Total # shRNA with >= 4-fold: 1 Resistant to T-cell proliferation
24476824shRNAmelanomaB16Secondary screen Total # shRNA with >= 4-fold: 5 Resistant to T-cell proliferation
Summary
SymbolEGR2
Nameearly growth response 2
Aliases Krox-20 homolog, Drosophila; KROX20; early growth response 2 (Krox-20 homolog, Drosophila); AT591; CMT1D; KR ......
Chromosomal Location10q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of EGR2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.8010.0601
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.4690.233
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.3110.741
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.9720.0527
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.930.567
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.0150.651
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0690.883
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1450.896
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2220.844
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.4090.0549
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.1880.0307
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3560.11
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of EGR2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolEGR2
Nameearly growth response 2
Aliases Krox-20 homolog, Drosophila; KROX20; early growth response 2 (Krox-20 homolog, Drosophila); AT591; CMT1D; KR ......
Chromosomal Location10q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of EGR2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolEGR2
Nameearly growth response 2
Aliases Krox-20 homolog, Drosophila; KROX20; early growth response 2 (Krox-20 homolog, Drosophila); AT591; CMT1D; KR ......
Chromosomal Location10q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of EGR2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by EGR2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolEGR2
Nameearly growth response 2
Aliases Krox-20 homolog, Drosophila; KROX20; early growth response 2 (Krox-20 homolog, Drosophila); AT591; CMT1D; KR ......
Chromosomal Location10q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of EGR2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolEGR2
Nameearly growth response 2
Aliases Krox-20 homolog, Drosophila; KROX20; early growth response 2 (Krox-20 homolog, Drosophila); AT591; CMT1D; KR ......
Chromosomal Location10q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of EGR2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolEGR2
Nameearly growth response 2
Aliases Krox-20 homolog, Drosophila; KROX20; early growth response 2 (Krox-20 homolog, Drosophila); AT591; CMT1D; KR ......
Chromosomal Location10q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between EGR2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolEGR2
Nameearly growth response 2
Aliases Krox-20 homolog, Drosophila; KROX20; early growth response 2 (Krox-20 homolog, Drosophila); AT591; CMT1D; KR ......
Chromosomal Location10q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting EGR2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.